6446 Stock Overview
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 6446 from our risk checks.
PharmaEssentia Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$300.00 |
| 52 Week High | NT$392.00 |
| 52 Week Low | NT$274.00 |
| Beta | 0.57 |
| 1 Month Change | -7.83% |
| 3 Month Change | -6.54% |
| 1 Year Change | -15.37% |
| 3 Year Change | 238.60% |
| 5 Year Change | 109.79% |
| Change since IPO | 43.00% |
Recent News & Updates
Recent updates
Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?
Apr 02
Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term
Mar 18PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 06Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade
Mar 04PharmaEssentia (GTSM:6446) Is Using Debt Safely
Feb 10What Type Of Returns Would PharmaEssentia's(GTSM:6446) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Jan 06
PharmaEssentia Corporation's (GTSM:6446) Profit Outlook
Nov 30Shareholder Returns
| 6446 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -2.3% | -0.7% | -1.6% |
| 1Y | -15.4% | -23.7% | 25.9% |
Return vs Industry: 6446 exceeded the TW Biotechs industry which returned -23.7% over the past year.
Return vs Market: 6446 underperformed the TW Market which returned 25.9% over the past year.
Price Volatility
| 6446 volatility | |
|---|---|
| 6446 Average Weekly Movement | 3.7% |
| Biotechs Industry Average Movement | 4.8% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.6% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6446 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6446's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Ko-Chung Lin | www.pharmaessentia.com |
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia.
PharmaEssentia Corporation Fundamentals Summary
| 6446 fundamental statistics | |
|---|---|
| Market cap | NT$99.57b |
| Earnings (TTM) | -NT$623.83m |
| Revenue (TTM) | NT$5.11b |
19.5x
P/S Ratio-159.6x
P/E RatioIs 6446 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6446 income statement (TTM) | |
|---|---|
| Revenue | NT$5.11b |
| Cost of Revenue | NT$610.54m |
| Gross Profit | NT$4.50b |
| Other Expenses | NT$5.12b |
| Earnings | -NT$623.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.88 |
| Gross Margin | 88.04% |
| Net Profit Margin | -12.22% |
| Debt/Equity Ratio | 0.4% |
How did 6446 perform over the long term?
See historical performance and comparison